Show simple item record

dc.contributor.authorZijlstra, Josée M
dc.contributor.authorFollows, George
dc.contributor.authorCasasnovas, Rene-Olivier
dc.contributor.authorVermaat, Joost SP
dc.contributor.authorKalakonda, Nagesh
dc.contributor.authorChoquet, Sylvain
dc.contributor.authorHill, Brian
dc.contributor.authorThieblemont, Catherine
dc.contributor.authorCavallo, Federica
dc.contributor.authorCruz, Fatima De la
dc.contributor.authorKuruvilla, John
dc.contributor.authorHamad, Nada
dc.contributor.authorJaeger, Ulrich
dc.contributor.authorCaimi, Paolo
dc.contributor.authorGurion, Ronit
dc.contributor.authorWarzocha, Krzysztof
dc.contributor.authorBakhshi, Sameer
dc.contributor.authorSancho, Juan-Manuel
dc.contributor.authorSchuster, Michael
dc.contributor.authorEgyed, Miklos
dc.contributor.authorOffner, Fritz
dc.contributor.authorVassilakopoulos, Theodoros P
dc.contributor.authorSamal, Priyanka
dc.contributor.authorKu, Matthew
dc.contributor.authorXu, Jenny
dc.contributor.authorCorona, Kelly
dc.contributor.authorChamoun, Kamal
dc.contributor.authorShah, Jatin
dc.contributor.authorCanales, Miguel
dc.contributor.authorMaerevoet, Marie
dc.date.accessioned2022-03-19T02:06:26Z
dc.date.available2022-03-19T02:06:26Z
dc.date.issued2022-02-04
dc.identifier.issn2072-6694
dc.identifier.other35159058
dc.identifier.otherPMC8834328
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/335207
dc.description.abstractSelinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed several categories of patient characteristics (age, renal function, DLBCL subtype, absolute lymphocyte count, transplant status, number of prior lines of therapy, refractory status, Ann Arbor disease stage, and lactate dehydrogenase) at baseline, i.e., during screening procedures, to determine their potential contributions to the efficacy (overall response rate [ORR], duration of response [DOR], overall survival [OS]) and tolerability of selinexor. Across most categories of characteristics, no significant difference was observed in ORR or DOR. OS was significantly longer for patients < 65 vs. ≥ 65 years, and for those with lymphocyte counts ≥ 1000/µL vs. < 1000/µL or lactate dehydrogenase ≤ ULN vs. > ULN. The most common adverse events (AEs) across the characteristics were thrombocytopenia and nausea, and similar rates of grade 3 AEs and serious AEs were observed. With its oral administration, novel mechanism of action, and consistency in responses in heavily pretreated patients, selinexor may help to address an important unmet clinical need in the treatment of DLBCL.
dc.languageeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 2072-6694
dc.sourcenlmid: 101526829
dc.subjectDiffuse Large B-cell Lymphoma
dc.subjectExportin 1
dc.subjectSelinexor
dc.subjectSadal Study
dc.titleThe Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
dc.typeArticle
dc.date.updated2022-03-19T02:06:26Z
prism.issueIdentifier3
prism.publicationNameCancers (Basel)
prism.volume14
dc.identifier.doi10.17863/CAM.82637
dcterms.dateAccepted2022-01-25
rioxxterms.versionofrecord10.3390/cancers14030791
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidZijlstra, Josée M [0000-0003-1074-5922]
dc.contributor.orcidCasasnovas, Rene-Olivier [0000-0002-1156-8983]
dc.contributor.orcidVermaat, Joost SP [0000-0002-1628-6256]
dc.contributor.orcidCavallo, Federica [0000-0003-2047-1099]
dc.contributor.orcidSancho, Juan-Manuel [0000-0001-7168-6538]
dc.identifier.eissn2072-6694
cam.issuedOnline2022-02-04


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International